• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immunotherapy: Does adjuvant ipilimumab have little adverse effect on quality of life?

作者信息

Lorigan Paul, Green Adele C

机构信息

University of Manchester and Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK.

Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK; and at the QIMR Berghofer Medical Research Institute, Royal Brisbane and Woman's Hospital, 300 Herston Road, Herston, Queensland 4029, Australia.

出版信息

Nat Rev Clin Oncol. 2017 Jul;14(7):395-396. doi: 10.1038/nrclinonc.2017.60. Epub 2017 Apr 25.

DOI:10.1038/nrclinonc.2017.60
PMID:28440331
Abstract
摘要

相似文献

1
Immunotherapy: Does adjuvant ipilimumab have little adverse effect on quality of life?免疫疗法：辅助性伊匹单抗对生活质量的不良影响小吗？
Nat Rev Clin Oncol. 2017 Jul;14(7):395-396. doi: 10.1038/nrclinonc.2017.60. Epub 2017 Apr 25.
2
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.辅助伊匹单抗对比安慰剂用于完全切除的高风险 III 期黑色素瘤（EORTC 18071）：一项随机、双盲、III 期临床试验。
Lancet Oncol. 2015 May;16(5):522-30. doi: 10.1016/S1470-2045(15)70122-1. Epub 2015 Mar 31.
3
Treatment of advanced melanoma with laser immunotherapy and ipilimumab.激光免疫疗法和伊匹单抗治疗晚期黑色素瘤
J Biophotonics. 2017 May;10(5):618-622. doi: 10.1002/jbio.201600271. Epub 2017 Apr 18.
4
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.纳武利尤单抗与伊匹木单抗联合用药对比伊匹木单抗单药治疗晚期黑色素瘤患者：一项多中心、随机、对照、2期试验的2年总生存结果
Lancet Oncol. 2016 Nov;17(11):1558-1568. doi: 10.1016/S1470-2045(16)30366-7. Epub 2016 Sep 9.
5
Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma.晚期黑色素瘤患者序贯使用伊匹单抗和派姆单抗治疗失败后，联合使用低剂量伊匹单抗和派姆单抗。
Eur J Cancer. 2016 Sep;65:182-4. doi: 10.1016/j.ejca.2016.07.003. Epub 2016 Aug 6.
6
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.伊匹单抗 10mg/kg 对比伊匹单抗 3mg/kg 治疗不可切除或转移性黑色素瘤患者：一项随机、双盲、多中心、III 期临床试验。
Lancet Oncol. 2017 May;18(5):611-622. doi: 10.1016/S1470-2045(17)30231-0. Epub 2017 Mar 27.
7
Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.使用氟代脱氧葡萄糖正电子发射断层扫描-计算机断层扫描（FDG PET-CT）进行伊匹单抗免疫治疗黑色素瘤时的免疫介导疾病
Acad Radiol. 2017 Jan;24(1):111-115. doi: 10.1016/j.acra.2016.08.005. Epub 2016 Nov 4.
8
Ipilimumab in anti-PD1 refractory metastatic melanoma: a report of eight cases.伊匹单抗治疗抗PD-1难治性转移性黑色素瘤：8例报告。
Melanoma Res. 2016 Apr;26(2):153-6. doi: 10.1097/CMR.0000000000000221.
9
Pembrolizumab use for the treatment of advanced melanoma.帕博利珠单抗用于治疗晚期黑色素瘤。
Expert Opin Biol Ther. 2017 Jun;17(6):765-780. doi: 10.1080/14712598.2017.1309388. Epub 2017 Apr 3.
10
Adjuvant ipilimumab in stage III melanoma: New landscape, new questions.III 期黑色素瘤的辅助性伊匹木单抗：新前景，新问题。
Eur J Cancer. 2016 Dec;69:39-42. doi: 10.1016/j.ejca.2016.10.009. Epub 2016 Nov 4.

引用本文的文献

1
Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: a systematic review.肿瘤免疫检查点抑制剂临床试验中使用的患者报告结局工具：一项系统评价
J Patient Rep Outcomes. 2020 Jul 16;4(1):58. doi: 10.1186/s41687-020-00210-z.
2
Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy.辅助树突细胞疗法治疗 III 期黑色素瘤患者的健康相关生活质量分析。
Clin Transl Oncol. 2019 Jun;21(6):774-780. doi: 10.1007/s12094-018-1987-0. Epub 2018 Nov 21.
3
Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report.

本文引用的文献

1
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.高危III期黑色素瘤完全切除术后辅助使用伊匹单抗与安慰剂相比的健康相关生活质量（EORTC 18071）：一项多国、随机、双盲、3期试验的次要结果
Lancet Oncol. 2017 Mar;18(3):393-403. doi: 10.1016/S1470-2045(17)30015-3. Epub 2017 Feb 3.
2
Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).T2bNO、T3a - bNO、T4a - bNO期以及T1 - 4N1a - 2a（微小）期黑色素瘤患者接受4周大剂量干扰素-α-2b治疗的III期随机研究：东部肿瘤协作组-美国放射学会影像网络癌症研究组（E1697）试验
J Clin Oncol. 2017 Mar 10;35(8):885-892. doi: 10.1200/JCO.2016.70.2951. Epub 2017 Jan 30.
抗 PD-1 诱导的与皮质类固醇耐药 T 细胞相关的高级别肝炎：一例报告。
Cancer Immunol Immunother. 2018 Apr;67(4):563-573. doi: 10.1007/s00262-017-2107-7. Epub 2017 Dec 30.
3
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.伊匹单抗辅助治疗Ⅲ期黑色素瘤的长期生存
N Engl J Med. 2016 Nov 10;375(19):1845-1855. doi: 10.1056/NEJMoa1611299. Epub 2016 Oct 7.
4
Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma.高危和转移性黑色素瘤的外科治疗及辅助治疗
Am Soc Clin Oncol Educ Book. 2016;35:e505-14. doi: 10.1200/EDBK_159087.
5
Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer.肺癌中与检查点抑制剂相关的免疫相关毒性的最佳管理
Lung Cancer. 2015 May;88(2):117-23. doi: 10.1016/j.lungcan.2015.02.007. Epub 2015 Feb 16.
6
Improved survival with ipilimumab in patients with metastatic melanoma.Ipilimumab 改善转移性黑色素瘤患者的生存。
N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5.
7
Final version of 2009 AJCC melanoma staging and classification.2009 年 AJCC 黑色素瘤分期与分类的最终版。
J Clin Oncol. 2009 Dec 20;27(36):6199-206. doi: 10.1200/JCO.2009.23.4799. Epub 2009 Nov 16.